[go: up one dir, main page]

WO2019242619A1 - Anticorps anti-lag-3 complètement humanisé et son application - Google Patents

Anticorps anti-lag-3 complètement humanisé et son application Download PDF

Info

Publication number
WO2019242619A1
WO2019242619A1 PCT/CN2019/091749 CN2019091749W WO2019242619A1 WO 2019242619 A1 WO2019242619 A1 WO 2019242619A1 CN 2019091749 W CN2019091749 W CN 2019091749W WO 2019242619 A1 WO2019242619 A1 WO 2019242619A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence
antibody
lag
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/091749
Other languages
English (en)
Chinese (zh)
Inventor
胡化静
缪小牛
张攀
刘军建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Priority to CN201980035403.0A priority Critical patent/CN112166125B/zh
Publication of WO2019242619A1 publication Critical patent/WO2019242619A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to novel antibodies and antibody fragments that specifically bind to LAG-3 and compositions containing said antibodies or antibody fragments.
  • the present invention relates to a nucleic acid encoding the antibody or an antibody fragment thereof, a host cell comprising the same, and related uses.
  • the invention relates to the therapeutic and diagnostic uses of these antibodies and antibody fragments.
  • the invention relates to the combination therapy of these antibodies and antibody fragments with other therapies, such as treatment modalities or therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.
  • Lymphocyte activating gene 3 (LAG-3), also known as CD223, is a type I transmembrane protein encoded by the LAG3 gene in humans.
  • LAG-3 is a CD4-like protein expressed on the surface of T cells (especially activated T cells), natural killer cells, B cells, and plasma cell-like dendritic cells.
  • LAG-3 has been shown to be a negative costimulatory receptor, that is, an inhibitory receptor.
  • CD8 + T cells that are depleted after chronic viral infection express multiple inhibitory receptors (such as PD-1, CD160, and 2B4).
  • LAG-3 was expressed at high levels after LCMV infection and showed that blocking the PD-1 / PD-L1 pathway and blocking LAG-3 significantly reduced viral load in chronically infected mice (Blackburn et al., Nat Immunol (2009 ) 10: 29-37). It has also been shown that the combined inhibition of the PD-1 / PD-L1 pathway and LAG-3 blockers provides antitumor efficacy (Jing et al., Journal for ImmunoTherapy of Cancer (2015) 3: 2).
  • the invention provides a fully human-derived anti-human LAG-3 antibody, a coding gene and application thereof.
  • the present inventors screened fully human antibodies against human LAG-3 from the human antibody library displayed on the surface of yeast, and further obtained high affinity matured on the basis of this Anti-human LAG-3 antibody.
  • the fully human antibody molecule of the present invention can effectively block the binding of LAG-3 to major histocompatibility (MHC) class II molecules, bind to LAG-3 expressed on activated human CD4 + T cells, and administer it in vivo Inhibition of tumor growth, especially when combined with anti-PD-1 antibodies, the tumor suppression effect is particularly significant. Therefore, the antibodies of the present invention can be used for a variety of purposes, including but not limited to detecting LAG-3 protein and inhibiting tumor growth in a tumor-bearing subject.
  • MHC major histocompatibility
  • the invention provides an antibody or antigen-binding fragment thereof that specifically binds LAG-3, preferably a human LAG-3 protein.
  • an antibody or antigen-binding fragment thereof of the invention that specifically binds human LAG-3 comprises:
  • the invention also provides an anti-LAG-3 antibody or antigen-binding fragment thereof having one or more of the following characteristics: (i) inhibition (e.g., competitive inhibition) of any of the antibodies listed in Table 3 and human LAG- 3 binding; (ii) epitope binding to the same or overlapping with any of the antibodies shown in Table 3; (iii) competition with any of the antibodies shown in Table 3 for binding to human LAG-3.
  • an antibody of the invention exhibits one or more of the following biological activities:
  • Binding to human LAG-3 with high affinity (i) Binding to human LAG-3 with a dissociation constant (Kd) of less than 100 ⁇ 10 -4 , such as 0.5 ⁇ 10 -4 to 50 ⁇ 10 -4 ; (iii) binding to human LAG-3 expressed on the cell surface with high affinity; (iv) blocking the binding of human LAG-3 to the cell surface MHCII molecule; (v) binding to activated CD4 + and / or expressing human LAG-3 CD8 + T cells; (vi) stimulate an immune response, preferably an antitumor immune response; (vii) inhibit tumor cells expressing human LAG-3, especially when used in combination with anti-PD1 antibodies.
  • the antibody exhibits at least two, more preferably at least three, four, five, and even more preferably all of the properties described above.
  • the present invention provides a nucleic acid encoding an antibody of the present invention or a fragment thereof, a vector comprising the nucleic acid, and a host cell comprising the vector.
  • the present invention also provides a method for preparing an antibody or a fragment thereof of the present invention.
  • the invention provides an immunoconjugate, a multispecific antibody, and a pharmaceutical composition comprising an antibody of the invention.
  • the invention also provides methods of stimulating an immune response in a subject, as well as methods of preventing or treating cancer or infection.
  • the invention also relates to a method for detecting LAG-3 in a sample.
  • Figure 1 shows the ability of the parent antibodies (ADI-26818, ADI-26822 and ADI-26836) to bind to hLAG-3 expressed on HEK293 cells by flow cytometry.
  • 25F7 is a control antibody.
  • Figure 2 shows the binding capacity of affinity-optimized anti-hLAG-3 antibodies to hLAG-3 expressed on HEK293 cells by flow cytometry.
  • 25F7 is a control antibody.
  • Figure 3 shows that anti-LAG-3 antibodies block the interaction of human MHCII (HLA-DR) and LAG-3 by flow cytometry detection.
  • Figure 4 shows the detection of the binding capacity of anti-LAG-3 antibodies to activated human CD4 + T cells by flow cytometry detection.
  • Figure 5 shows the tumor suppressive effect of anti-LAG-3 antibodies in the A375-human PBMC model.
  • ADI-31798 is an antibody of the invention.
  • Antibody is an anti-PD-1 antibody ("Antibody D") disclosed in PCT / CN2016 / 094122.
  • Figure 6 shows a comparison of the VL regions of exemplary antibodies of the invention.
  • Figure 7 shows a comparison of VH regions of exemplary antibodies of the invention.
  • the term “comprising” or “including” means including the recited elements, integers, or steps, but does not exclude any other elements, integers, or steps.
  • the term “comprising” or “including” is used, unless otherwise indicated, the case consisting of the mentioned elements, integers, or steps is also covered.
  • an antibody variable region that "comprises” a particular sequence it is also intended to encompass an antibody variable region consisting of that particular sequence.
  • antibody refers to a polypeptide comprising at least a light or heavy chain immunoglobulin variable region that specifically recognizes and binds an antigen.
  • the term encompasses a variety of antibody structures including, but not limited to, monoclonal antibodies, polyclonal antibodies, single-chain or multi-chain antibodies, monospecific or multispecific antibodies (e.g., bispecific antibodies), fully human antibodies, or Chimeric antibodies or humanized antibodies, full-length antibodies, and antibody fragments are sufficient as long as they exhibit the desired antigen-binding activity.
  • “whole antibodies” (which are used interchangeably herein with “full-length antibodies”, “full antibodies” and “full antibodies”) comprise at least two heavy chains (H) and two light chains ( L).
  • Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region.
  • the heavy chain constant region consists of three domains, CH1, CH2, and CH3.
  • Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region.
  • the light chain constant region consists of a domain CL.
  • a variable region is a domain in the heavy or light chain of an antibody that is involved in the binding of the antibody to its antigen.
  • the constant region does not directly participate in the binding of the antibody to the antigen, but displays a variety of effector functions.
  • the light chain of an antibody can be classified into one of two types (called kappa ( ⁇ ) and lambda ( ⁇ )) based on the amino acid sequence of its constant domain.
  • the heavy chain of an antibody can be divided into five major types depending on the amino acid sequence of the constant region of its heavy chain: IgA, IgD, IgE, IgG, and IgM, and several of these types can be further divided into subclasses, such as , IgG1, IgG2, IgG3 and IgG4, IgA1 and IgA2.
  • the heavy chain constant regions corresponding to different antibody types are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
  • the term "isotype" refers to the type of antibody determined by the constant region of the antibody heavy chain. See, for example, Fundamental Immunology, Ch. 7 (Editor Paul, W., Second Edition, Raven Press, N.Y. (1989)) (which is incorporated herein by reference in its entirety for all purposes).
  • antigen-binding portion of an antibody refers to a molecule that is not an intact antibody, which contains the intact antibody used to bind the intact antibody Part of the antigen.
  • the antigen-binding portion of an antibody typically contains amino acid residues from a "complementarity determining region" or "CDR".
  • Antigen-binding fragments can be prepared by recombinant DNA technology, or by enzymatic or chemical cleavage of whole antibodies.
  • Antigen-binding fragments include, but are not limited to, Fab, scFab, Fab ', F (ab') 2 , Fab'-SH, Fv, single-chain Fv, double-chain antibody (diabody), triple-chain antibody (triabody), four-chain antibody ( tetrabody), minibody, single domain antibody (sdAb).
  • human antibody or “fully human antibody” are used interchangeably herein and refer to antibodies that include variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Moreover, if the antibody contains a constant region, the constant region is also derived from a human germline immunoglobulin sequence.
  • the human antibodies of the invention may include amino acid sequences that are not encoded by human germline immunoglobulin sequences (eg, mutations introduced by random or point-specific mutagenesis in vitro or somatic mutations in vivo), such as in CDRs-especially CDR3.
  • the term "human antibody” does not include antibodies in which the CDR sequences are derived from the germline of other mammalian species (eg, mice) and transplanted into human framework sequences.
  • recombinant human antibody includes all human antibodies that are produced, expressed, produced, or isolated by recombinant means, for example, (a) an animal (e.g., a mouse) that has been transgenic or transchromosomic with a human immunoglobulin gene or Antibodies isolated from hybridomas prepared therefrom, (b) antibodies isolated from host cells transformed into human antibody expression such as transfected tumors, (c) antibodies isolated from recombinant, combined human antibody libraries such as yeast display libraries, and ( d) An antibody prepared, expressed, produced or isolated by any other means, including splicing of human immunoglobulin genes to other DNA sequences.
  • recombinant human antibodies have framework regions and CDR regions that are derived from variable regions of human germline immunoglobulin sequences.
  • the recombinant human antibody can be subjected to in vitro mutagenesis (or in vivo somatic mutagenesis when using human Ig sequence transgenic animals), and the amino acid sequences of the VH and VL regions of the recombinant antibody thus obtained, although derived from and related to human germline VH and VL sequences, they are not naturally found in human antibody germline libraries in vivo.
  • monoclonal antibody refers herein to antibodies obtained from a substantially homogeneous population of antibodies, i.e., in addition to possible variant antibodies (e.g., containing natural mutations or in the production of monoclonal antibody preparations) that are usually present in very small amounts Except for variant antibodies generated during the process, the individual antibodies constituting the population are the same and / or bind the same epitope.
  • chimeric antibody refers to an antibody in which the variable region sequence is derived from one species and the constant region sequence is derived from another species, for example, an antibody in which the variable region sequence is derived from a mouse antibody and the constant region sequence is derived from a human antibody .
  • humanized antibody refers to an antibody that attaches CDR sequences derived from other mammalian species, such as mouse germline, to human framework sequences. Additional framework region modifications can be made within the human framework sequence.
  • an “isolated” antibody is one that has been separated from components in its natural environment.
  • the antibody is purified to greater than 95% or 99% purity by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase Phase HPLC).
  • electrophoresis e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatography e.g., ion exchange or reversed-phase Phase HPLC
  • epitope refers to the region of an antigen to which an antibody binds.
  • An epitope can be formed from consecutive amino acids or non-contiguous amino acids juxtaposed by the tertiary folding of a protein.
  • lymphocyte activating gene-3 and “LAG-3” are used interchangeably and include variants, isotypes, homologs, and species homologs of LAG-3.
  • human LAG-3 refers to the human sequence LAG-3, for example, the complete amino acid sequence of human LAG-3 under Genbank accession number NP_002277. The human LAG-3 sequence may be different from the human LAG-3 of Genbank Accession No.
  • NP_002277 in that it has, for example, a conservative mutation or a mutation in a non-conserved region, but still has substantially the same biological function, for example, in the extracellular domain It has an epitope that specifically binds to the antibody of the present invention, or has the function of binding to MHC class II molecules.
  • the human LAG-3 sequence is at least 90% identical to the human LAG-3 amino acid sequence of Genbank Accession No. NP_002277, and contains the amino acid sequence that can be identified when compared with the LAG-3 amino acid sequence of other species (rats) Is the amino acid residue of the human amino acid sequence.
  • the human LAG-3 sequence has at least 95%, even at least 96%, 97%, 98%, or 99% amino acid sequence identity with the human LAG-3 amino acid sequence of Genbank accession number NP_002277.
  • LAG-3 proteins may also include fragments of LAG-3, such as fragments containing extracellular domains as well as extracellular domains, such as fragments that retain the ability to bind to any antibody of the invention, such as soluble LAG-3 molecules.
  • immune response refers to, for example, the action of lymphocytes, antigen-presenting cells, phagocytes, granulocytes, and soluble macromolecules (including antibodies, cytokines, and complements) produced by the above-mentioned cells or liver, which results in selective Damage, destruction, or removal of invading pathogens, cells or tissues infected with pathogens, or cancer cells.
  • the term "specific binding” means that an antibody selectively or preferentially binds an antigen. If in the bio-optical interferometry, the antibody is about 5x 10 -7 M or lower, about 1x 10 -7 M or lower, about 5x 10 -8 M or lower, about 1x 10 -8 M or lower, A K D of about 5x 10 -9 M or lower, which binds to human LAG-3, then the antibody is an antibody that "specifically binds to human LAG-3".
  • antibodies that specifically bind human LAG-3 can be cross-reactive with LAG-3 proteins from other species. For example, antibodies specific for human LAG-3 may, in some embodiments, cross-react with LAG-3 proteins of non-human species. In other embodiments, human LAG-3 specific antibodies can be completely specific to human LAG-3 without showing species or other types of cross-reactivity, or showing only cross-reactivity to LAG-3 of certain species Reactivity.
  • affinity or "binding affinity” refers to the inherent binding affinity that reflects the interaction between members of a binding pair.
  • the affinity of a molecule X for its partner Y can generally be represented by an equilibrium dissociation constant (K D ), which is the ratio of the dissociation rate constant and the association rate constant (k dis and k on, respectively ).
  • K D equilibrium dissociation constant
  • k dis and k on, respectively association rate constant
  • Affinity can be measured by common methods known in the art.
  • One specific method for measuring affinity is the ForteBio kinetic binding assay herein.
  • high affinity for IgG antibodies means that the antibody is at 1x 10 -7 M or lower, preferably 5x 10 -8 M or lower, more preferably about 1x 10 -8 M or lower, even more preferably Ground K D of about 5x 10 -9 M or lower, binds to the target antigen.
  • “high-affinity” binding can vary with antibody isotype.
  • the IgM isotype “high affinity” refers to an antibody having 1x 10 -6 M or lower, preferably 1x 10 -7 M or less, more preferably about 1x 10 -8 M or less K D .
  • a “competitively bound antibody” to a reference antibody that binds to an antigen such as LAG-3 refers to an antibody that blocks 50% or more of the binding of the reference antibody to an antigen (such as LAG-3) in a competition test, And, in turn, a reference antibody blocks 50% or more of the antibody's binding to an antigen (eg, LAG-3) in a competition test.
  • Exemplary competition tests are described in: "Antibodies”, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, NY).
  • Competitively bound antibodies may bind the same epitope region as the reference antibody, such as the same epitope, adjacent epitopes, or overlapping epitopes.
  • Fc region is used herein to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of a constant region.
  • the term includes natural sequence Fc-regions and variant Fc-regions.
  • the human IgG heavy chain Fc-region extends from Cys226 of the heavy chain or from Pro230 to the carboxy terminus.
  • the C-terminal lysine (Lys447) of the Fc-region may or may not be present.
  • the numbering of amino acid residues in the Fc-region or constant region is based on the EU numbering system, also known as the EU index, such as Kabat, EA, etc. , National Institute of Health, Bethesda, MD (1991), NIH Publication 91-3242.
  • variant in relation to an antibody means herein that, as compared to a reference antibody, it has passed at least 1 An antibody having a target antibody region of amino acid change with 5 amino acid substitutions, deletions, and / or insertions, wherein the variant substantially retains at least one biological property (eg, antigen-binding ability) of the antibody molecule before the change.
  • the target antibody region can be the full length of the antibody, or the heavy or light chain variable region or a combination thereof, or the heavy chain CDR region (s) or the light chain CDR region (s) or a combination thereof .
  • An antibody region having an amino acid change relative to a reference antibody region is also referred to herein as a "variant" of the antibody region.
  • sequence identity refers to the degree to which sequences are identical on a nucleotide-by-nucleotide or amino-acid-based basis in a comparison window.
  • the "percent sequence identity” can be calculated by comparing two optimally aligned sequences in a comparison window to determine the presence of the same nucleic acid base in both sequences (for example, A, T, C, G, I ) Or the same amino acid residue (for example, Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) The number of positions to get the number of matching positions, divides the number of matching positions by the total number of positions in the comparison window (ie, the window size), and multiplies the result by 100 to produce a percent sequence identity.
  • the optimal alignment for determining the percent sequence identity can be achieved in a variety of ways known in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine suitable parameters for aligning sequences, including any algorithms needed to achieve maximum alignment within the full-length sequence range being compared or within the region of the target sequence.
  • the percent amino acid sequence identity is determined by optimally aligning the candidate antibody sequence with the reference antibody sequence, and performing optimal alignment in accordance with the Kabat numbering rule in a preferred scheme.
  • the target antibody region on the reference antibody eg, the entire variable region of the heavy or light chain, or a portion thereof, such as one or more CDR regions
  • the percent sequence identity between the candidate antibody region and the reference antibody region is: the number of positions occupied by the same amino acid in both the candidate antibody region and the reference antibody region divided by the total number of aligned positions of the two regions (the gaps are not counted) ) And multiply by 100 to get the percentage.
  • a candidate antibody and the reference antibody have an X% sequence identity in a region corresponding to the target antibody region of the reference antibody after being compared, the candidate antibody is considered to be a reference antibody.
  • An antibody with X% sequence identity on the target antibody region In this context, without specifying the region of the target antibody, it will be suitable for alignment over the full length of the reference antibody sequence.
  • sequence identity may be distributed over the entire heavy chain variable region and / or the entire light chain variable region, or the percent sequence identity may be limited to the framework region only, while corresponding CDR regions The sequence remains 100% identical.
  • candidate antibodies with amino acid changes in the target antibody region relative to the reference antibody can be determined. Therefore, in this paper, if a candidate antibody has a comparison with a reference antibody with X amino acid changes in a region corresponding to the target antibody region (such as the CDR region) of the reference antibody, the candidate antibody is considered to be An antibody that has an X amino acid change in the target antibody region with a reference antibody. When X is 0, the candidate antibody is considered to have the same target antibody region as the reference antibody. For example, when the target antibody region is a CDR sequence, the candidate antibody is considered to be an antibody having the same CDR sequence as the reference antibody.
  • “conservative substitution” refers to an amino acid change that results in the replacement of a certain amino acid with a chemically similar amino acid.
  • Amino acid modifications, such as substitutions can be introduced into the antibodies of the invention by standard methods known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • conservative substitution residues are from the conservative substitution table A below, preferably the preferred conservative substitution residues shown in Table A.
  • an antibody or antigen-binding fragment thereof that specifically binds LAG-3, preferably a human LAG-3 protein, especially a fully human antibody or fragment thereof.
  • the antigen-binding fragment of an antibody of the invention is an antibody fragment selected from the group consisting of Fab, Fab ', Fab'-SH, Fv, single chain antibodies such as scFv, (Fab') 2 fragments, single domain antibodies , Diabody (dAb) or linear antibody.
  • the anti-LAG-3 antibodies or fragments thereof of the present invention bind to human LAG-3 with high affinity
  • the dissociation equilibrium constant (K D ) is less than about 100 nM, less than or equal to about 50 nM, more preferably Less than or equal to about 20nM, 15nM, or 10nM, such as 0.1-20nM, more preferably less than or equal to about 5nM, 4nM, 3nM, or 2nM, preferably 0.5-3nM, and even more preferably, less than or equal to about 1nM, 0.5nM.
  • K D is determined by using a bio-optic interferometry (for example, Fortebio affinity measurement).
  • the antibody or LAG-3 binding fragment of the present invention solutions of the dissociation constant (K dis) of less than 100 ⁇ 10 -4, 60 ⁇ 10 -4, for example, 0.5 ⁇ 10 -4 to 50 ⁇ 10 - 4 , preferably 1 ⁇ 10 -4 to 10 ⁇ 10 -4 , or 1 ⁇ 10 -4 to 6 ⁇ 10 -4 s -1 , such as about 5 ⁇ 10 -4 s -1 .
  • K dis dissociation constant
  • the binding constant (K on ) of the anti-LAG-3 antibody molecule to human LAG-3 is greater than 0.5 ⁇ 10 5 , 1 ⁇ 10 5 , 2 ⁇ 10 5 , 3 ⁇ 10 5 , 4 ⁇ 10 5 Or 5 ⁇ 10 5 M -1 s -1 , for example, bound to human LAG-3 with a K on of about 5 ⁇ 10 5 M -1 s -1 .
  • K dis and K on are determined by using a bio-optic interferometry (for example, Fortebio affinity measurement).
  • the antibodies or fragments thereof of the invention bind to cells expressing LAG-3 with high affinity.
  • the cells that express human LAG-3 on the surface are 293 cells, such as HEK293 cells.
  • the EC50 value of the antibody binding to human LAG-3 expressing HEK293 cells is less than about 50 nM, 30 nM, or 10 M, such as 0.1-10 nM, preferably less than or equal to about 8 nM, as determined by flow cytometry (eg, FACS) 5nM, 3nM, or 2nM, more preferably less than or equal to about 1.5nM, 1.2nM, or 1nM, even more preferably less than or equal to about 0.8nM, 0.6nM, 0.3M, or 0.2nM.
  • the present invention is an antibody or fragment thereof inhibits related activity of LAG-3, for example, IC 50 values of less than or equal to about 20nM, 10nM, 9nM, 8nM, 7nM, 6nM , or of 5 nM, more preferably IC 50 of less than or equal to about 1-7nM, 1-5nM, 6.5nM, 6nM, 5.5nM, 5nM, 4.5nM, 4nM, 3.5nM, or 3nM.
  • the related activity of LAG-3 is the binding of MHC class II molecules to LAG-3.
  • the antibodies or fragments thereof of the invention are less than or equal to about 20 nM, 10 nM, such as 1-9 nM, such as 1-8 nM, more preferably about 1-7 nM, 1-2 nM, for example, less than or equal to 6.5 nM , 6nM, 5.5nM, 5nM, 4.5nM , 4nM, 3.5nM 3nM or the IC 50, MHCII binding molecules on the cell block human MHCII molecules of LAG-3 expression.
  • the MHC class II molecule is HLA-DR.
  • the cell is a CHO cell.
  • the inhibition of LAG-3 related activity by an antibody of the invention or a fragment thereof is measured using flow cytometry (e.g., FACS).
  • an antibody or fragment thereof of the invention binds to activated CD4 + and / or CD8 + T cells that express human LAG-3 on the surface.
  • the EC50 value of the antibody binding to activated human CD4 + T cells is less than or equal to about 35 pM, 30 pM, 25 pM, 20 pM, 15 pM, or 10 pM, preferably about 1-20 pM, as determined by flow cytometry (eg, FACS). 6-15 pM, 6-10 pM, for example, less than or equal to about 12 pM, 11 pM, 10 pM, 9 pM, 8 pM, 7 pM, 6 pM, or 5 pM.
  • flow cytometry is performed in the Accuri C6 system.
  • an antibody or fragment thereof of the invention inhibits one or more activities of LAG-3, for example, causing one or more of the following: increased antigen-dependent stimulation of CD4 + T lymphocytes; T cell proliferation Increased expression of activated antigens (eg, CD25); increased expression of cytokines (eg, interferon- ⁇ (IFN- ⁇ ), interleukin-2 (IL-2), or interleukin-4 (IL-4)); Increased expression of chemokines (eg, CCL3, CCL4, or CCL5); reduced suppressive activity of Treg cells; increased T cell homeostasis; increased tumor infiltrating lymphocytes; or decreased immune escape from cancer cells.
  • activated antigens eg, CD25
  • cytokines eg, interferon- ⁇ (IFN- ⁇ ), interleukin-2 (IL-2), or interleukin-4 (IL-4)
  • chemokines eg, CCL3, CCL4, or CCL5
  • the antibodies or fragments thereof of the invention inhibit the growth of tumor cells expressing human LAG-3.
  • the tumor cell is a skin cancer cell, preferably a human skin cancer cell.
  • in vivo tumor transplantation models such as NOG mice, inhibit the growth of human skin cancer cells.
  • an antibody of the invention is used in combination with an anti-PD1 antibody to achieve a significantly better antitumor effect than when an antibody is administered alone.
  • an antibody of the invention or an antigen-binding fragment thereof exhibits at least one, more preferably at least two, more preferably at least three, four, or five, even more preferably all of the properties described above.
  • a “complementarity determining region” or “CDR region” or “CDR” (which is used interchangeably with the hypervariable region “HVR” herein) is an amino acid region in an antibody variable region that is mainly responsible for binding to an epitope.
  • the CDRs of the heavy and light chains are commonly referred to as CDR1, CDR2, and CDR3, and are numbered sequentially from the N-terminus.
  • the CDRs located in the variable domain of the antibody heavy chain are called HCDR1, HCDR2, and HCDR3, while the CDRs located in the variable domain of the antibody light chain are called LCDR1, LCDR2, and LCDR3.
  • CDR complementarity determining region
  • the HVR can also be an HVR sequence located at the following Kabat residue positions according to the Kabat numbering system:
  • Positions 24-36 or 24-34 (LCDR1) in VL, positions 46-56 or 50-56 (LCDR2), and positions 89-97 or 89-96 (LCDR3); and positions 26-35 or in VH 27-35B (HCDR1), positions 50-65 or 49-65 (HCDR2), and positions 93-102, 94-102, or 95-102 (HCDR3).
  • the HVR of an antibody of the invention is an HVR sequence located at the following Kabat residue position according to the Kabat numbering system:
  • the HVR of an antibody of the invention is an HVR sequence located at the following Kabat residue position according to the Kabat numbering system:
  • HVRs can also be determined based on having the same Kabat numbering position as a reference CDR sequence (such as any of the exemplary CDRs of the invention).
  • CDR or “CDR sequence” or “HVR” or “HVR sequence” encompasses HVR or CDR sequences determined in any of the ways described above.
  • variable region residues when referring to the position of residues in the variable region of an antibody (including heavy chain variable region residues and light chain variable region residues), it means according to the Kabat numbering system ( Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institute of Health, Bethesda, Md. (1991)).
  • the CDR sequences of the present invention are shown in Table 1.
  • the CDR sequences of the invention are shown in Table 2.
  • Antibodies with different specificities have different CDRs.
  • CDRs differ from antibody to antibody, only a limited number of amino acid positions within the CDR are directly involved in antigen binding.
  • the minimum binding unit may be a sub-portion of the CDR.
  • the residues of the rest of the CDR sequence can be determined by the structure and protein folding of the antibody. Accordingly, the invention also contemplates any variant of the CDRs given herein. For example, in one CDR variant, the amino acid residues of the smallest binding unit may remain unchanged, while the remaining CDR residues as defined by Kabat or Chothia may be replaced by conservative amino acid residues.
  • the antibodies of the invention have at least one, two, three, four, five, or six CDRs that are the same as the corresponding CDRs of any of the antibodies listed in Table 3, or are variants thereof.
  • an antibody of the invention has at least one, two, or three HCDRs that are the same as the corresponding heavy chain CDRs of any of the antibodies listed in Table 3, or are variants thereof.
  • the antibodies of the invention have at least one, two, or three LCDRs that are the same as the corresponding light chain CDRs of any of the antibodies listed in Table 3, or are variants thereof.
  • corresponding CDR refers to a CDR that is located at the most similar position to the CDR of the reference antibody in the amino acid sequence of the variable region of the candidate antibody after optimal alignment.
  • a CDR variant is a CDR that has been modified by at least one, such as 1 or 2 or 3 amino acid substitutions, deletions, and / or insertions, wherein the antigen-binding molecule comprising the CDR variant substantially remains unmodified
  • the biological properties of the antigen-binding molecule for example, maintain at least 60%, 70%, 80%, 90%, or 100% biological activity (eg, antigen-binding capacity). It is understood that each CDR can be modified individually or in combination.
  • amino acid modification is an amino acid substitution, especially a conservative amino acid substitution, such as the preferred conservative amino acid substitutions listed in Table A.
  • amino acid substitutions preferably occur at positions corresponding to the X residues of the consensus CDR sequences provided herein (e.g., SEQ ID NO: 16, 17, 18, 19, 20, 21, 30, 31, 32). Amino acid position.
  • the CDR3 region independent of the CDR1 and / or CDR2 regions, alone can determine the binding specificity of an antibody to an associated antigen. And, based on a common CDR3 sequence, a variety of other antibodies can be produced with the same binding specificity. See, for example, US Patents Nos. 6,951,646; 6,914,128; 6,090,382; 6,818,216; 6,156,313; 6,827,925; 5,833,943; 5,762,905, and 5,760,185. All of these references are incorporated herein by reference.
  • an antibody of the invention comprises CDR3 from the heavy and / or light chain variable regions of one of the antibodies shown in Table 3, wherein the antibody is capable of specifically binding human LAG-3.
  • the antibodies may further comprise CDR2 from the heavy and / or light chain variable regions of the same antibody, or from the heavy and / or light chain variable regions of different LAG-3 antibodies.
  • CDR2 from the heavy and / or light chain variable regions of the same antibody, or from the heavy and / or light chain variable regions of different LAG-3 antibodies.
  • the antibodies may further comprise CDR1s from the heavy and / or light chain variable regions of the same antibody, or from the heavy and / or light chain variable regions of different LAG-3 antibodies.
  • CDR1s from the heavy and / or light chain variable regions of the same antibody, or from the heavy and / or light chain variable regions of different LAG-3 antibodies.
  • the activity of these antibodies can be characterized by the assay methods described herein, including the binding activity to human LAG-3, the activity to block the binding of LAG
  • the VHCDR1, 2 and 3 sequences and the VLCDR1, 2 and 3 sequences can be "mixed and matched" (ie It is possible to mix and match CDRs from different antibodies that bind to the same LAG-3 antigen, although each antibody preferably contains VH (CDR1, 2 and 3 and VL (CDR1, 2 and 3)) to produce other LAG-3 binding of the present invention. molecule.
  • the binding of such "mixed and matched" antibodies to LAG-3 can be tested using binding assays known in the art (eg, ELISA, SET, Biacore) and those described in the examples.
  • the CDR1, CDR2 and / or CDR3 sequences from a particular VH sequence are preferably replaced with structurally similar CDR sequences.
  • the CDR1, CDR2 and / or CDR3 sequences from a particular VL sequence are preferably replaced with structurally similar CDR sequences. "Mixing and matching" of the CDRs can be performed between the antibodies shown in Table 3 of the present invention.
  • the structurally similar CDR sequences of the antibodies shown herein can also be replaced by one or more VH and / or VL CDR region sequences from other different antibodies to generate other antibody.
  • an antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region comprising a heavy chain complementarity determining region 3 (HCDR3), said HCDR3:
  • HCDR3 contains at least 1 and no more than 3 (preferably 1-2 or more preferably 1) amino acid changes (preferably substitutions, more preferably conservative substitutions).
  • the HCDR3 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, and 21.
  • an antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region and a light chain variable region, and the antibody has a heavy chain complementarity determining region 3 (HCDR3) and a light chain complementarity determining region 3 ( LCDR3):
  • HCDR3 heavy chain complementarity determining region 3
  • LCDR3 light chain complementarity determining region 3
  • HCDR3 and LCDR3 comprise an amino acid sequence combination selected from the group consisting of: SEQ ID NO: 3/24, 6/24, 18/24, 9/25, 9/26, 9/30, 12/28, 15 / 29 and 21/32 amino acid sequences.
  • an antibody of the invention or an antigen-binding fragment thereof comprises a heavy chain variable region (VH), wherein the VH comprises:
  • an antibody of the invention or an antigen-binding fragment thereof comprises a light chain variable region (VL), wherein the VL comprises:
  • an antibody of the invention or an antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the antibody comprises:
  • an antibody or antigen-binding fragment thereof of the invention comprises:
  • the antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR1 sequence from the heavy chain variable region of SEQ ID NO: 33 , CDR2 sequence, and CDR3 sequence, and the light chain variable region comprises a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence from the light chain variable region of SEQ ID NO: 39.
  • the antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR1 sequence from the heavy chain variable region of SEQ ID NO: 34 , CDR2 sequence, and CDR3 sequence, and the light chain variable region comprises a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence from the light chain variable region of SEQ ID NO: 39.
  • the antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR1 sequence from the heavy chain variable region of SEQ ID NO: 35 , CDR2 sequence, and CDR3 sequence, and the light chain variable region comprises a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence from the light chain variable region of SEQ ID NO: 40.
  • the antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR1 sequence from the heavy chain variable region of SEQ ID NO: 36 CDR2 sequence, and CDR3 sequence, and the light chain variable region comprises a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence from the light chain variable region of SEQ ID NO: 41.
  • the antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR1 sequence from the heavy chain variable region of SEQ ID NO: 37 CDR2 sequence, and CDR3 sequence, and the light chain variable region comprises a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence from the light chain variable region of SEQ ID NO: 42.
  • the antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR1 sequence from the heavy chain variable region of SEQ ID NO: 38 , CDR2 sequence, and CDR3 sequence, and the light chain variable region comprises a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence from the light chain variable region of SEQ ID NO: 43.
  • an anti-LAG-3 antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region (VH), wherein the VH comprises
  • a heavy chain HCDR combination selected from the following amino acid sequence combinations (in the order HCDR1, HCDR2, and HCDR3, respectively):
  • a heavy chain HCDR combination selected from the following amino acid sequence combinations (in the order HCDR1, HCDR2, and HCDR3, respectively):
  • an anti-LAG-3 antibody or antigen-binding fragment thereof of the invention comprises a light chain variable region (VL), wherein the VL comprises:
  • a light chain LCDR combination selected from the following amino acid sequence combinations (in the order LCDR1, LCDR2, and LCDR3, respectively):
  • an anti-LAG-3 antibody or antigen-binding fragment thereof of the invention comprises:
  • a combination of heavy and light chain CDRs selected from the following amino acid sequence combinations (in the order HCDR1, HCDR2 and HCDR3, LCDR1, LCDR2 and LCDR3, respectively):
  • a heavy and light chain CDR combination selected from the following amino acid sequence combinations (in the order HCDR1, HCDR2, and HCDR3, LCDR1, LCDR2, and LCDR3, respectively):
  • the antibody or antigen-binding fragment thereof of the present invention comprises three complementarity determining regions HCDRs of the variable region of the heavy chain, and three complementarity determining regions LCDR of the variable region of the light chain, wherein
  • HCDR1 contains the amino acid sequence shown in SEQ ID NO: 1 or 4 or 16 or 70 or 72; HCDR2 contains the amino acid sequence shown in SEQ ID NO: 2 or 5 or 17; HCDR3 contains SEQ ID No: 3 or 6 Or the amino acid sequence shown in 18 or 71 or 73, LCDR1 contains the amino acid sequence shown in SEQ ID NO: 22 or 31, LCDR2 contains the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 contains SEQ ID No: 24 The amino acid sequence of;
  • HCDR1 contains the amino acid sequence shown in SEQ ID NO: 7 or 74
  • HCDR2 contains the amino acid sequence shown in SEQ ID NO: 8
  • HCDR3 contains the amino acid sequence shown in SEQ ID NO: 9 or 75
  • LCDR1 contains SEQ ID The amino acid sequence shown by NO: 22 or 31
  • LCDR2 contains the amino acid sequence shown by SEQ ID NO: 23
  • LCDR3 contains the amino acid sequence shown by SEQ ID NO: 25 or 26 or 30; or
  • HCDR1 contains the amino acid sequence shown in SEQ ID NO: 10 or 13 or 19 or 76 or 78
  • HCDR2 contains the amino acid sequence shown in SEQ ID NO: 11 or 14 or 20
  • HCDR3 contains SEQ ID No: 12 or 15 Or the amino acid sequence shown in 21 or 77 or 79
  • LCDR1 contains the amino acid sequence shown in SEQ ID NO: 27 or 31
  • LCDR2 contains the amino acid sequence shown in SEQ ID NO: 23
  • LCDR3 contains SEQ ID No: 28 or 29 Or the amino acid sequence shown in 32.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 1; the HCDR2 sequence of SEQ ID NO: 2; the HCDR3 sequence of SEQ ID NO: 3; the sequence of SEQ ID NO: 22 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 24.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 70; the HCDR2 sequence of SEQ ID NO: 2; the HCDR3 sequence of SEQ ID NO: 71; the sequence of SEQ ID NO: 22 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 24.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 4; the HCDR2 sequence of SEQ ID NO: 5; the HCDR3 sequence of SEQ ID NO: 6; the SEQ ID NO: 22 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 24.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 72; the HCDR2 sequence of SEQ ID NO: 5; the HCDR3 sequence of SEQ ID NO: 73; the sequence of SEQ ID NO: 22 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 24.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NQ: 7; the HCDR2 sequence of SEQ ID NO: 8; the HCDR3 sequence of SEQ ID NO: 9; the sequence of SEQ ID NO: 22 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 25.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 74; the HCDR2 sequence of SEQ ID NO: 8; the HCDR3 sequence of SEQ ID NO: 75; the sequence of SEQ ID NO: 22 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 25.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 7; the HCDR2 sequence of SEQ ID NO: 8; the HCDR3 sequence of SEQ ID NO: 9; the sequence of SEQ ID NO: 22 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 26.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 74; the HCDR2 sequence of SEQ ID NO: 8; the HCDR3 sequence of SEQ ID NO: 75; the sequence of SEQ ID NO: 22 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 26.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 10; the HCDR2 sequence of SEQ ID NO: 11; the HCDR3 sequence of SEQ ID NO: 12; the sequence of SEQ ID NO: 27 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 28.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 76; the HCDR2 sequence of SEQ ID NO: 11; the HCDR3 sequence of SEQ ID NO: 77; the SEQ ID NO: 27 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 28.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 13; the HCDR2 sequence of SEQ ID NO: 14; the HCDR3 sequence of SEQ ID NO: 15; the sequence of SEQ ID NO: 27 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 29.
  • the antibody or antigen-binding fragment thereof of the present invention comprises: the HCDR1 sequence of SEQ ID NO: 78; the HCDR2 sequence of SEQ ID NO: 14; the HCDR3 sequence of SEQ ID NO: 79; the SEQ ID NO: 27 LCDR1 sequence; LCDR2 sequence of SEQ ID NO: 23; LCDR3 sequence of SEQ ID NO: 29.
  • a “variable region” or “variable domain” is a domain in the heavy or light chain of an antibody that is involved in the binding of the antibody to its antigen.
  • the heavy chain variable region (VH) and light chain variable region (VL) can be further divided into hypervariable regions (HVR, also known as complementarity determining regions (CDRs)) with a more conservative region (i.e., framework (FR)).
  • HVR hypervariable regions
  • FR framework
  • Each VH and VL consists of three CDRs and four FRs, arranged from the amino terminal to the carboxy terminal in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In some cases, a single VH or VL domain is sufficient to confer antigen-binding specificity.
  • antibodies that bind to a specific antigen can be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains (see, for example, Portolano, S. et al., J. Immunol. 150 (1993 880-887; Clackson, T. et al., Nature 352 (1991) 624-628).
  • one or more residues in one or both of the two variable regions can be modified, for example, to one or more CDR regions and / or to one Or multiple framework regions are subject to residue modification, especially conservative residue substitution, and the modified antibody still substantially retains at least one biological property (eg, antigen-binding ability) of the previous antibody molecule.
  • residues in the CDR regions can be mutated to improve one or more binding properties (e.g., affinity) of the antibody.
  • the antibody-binding or other functional properties of the mutated antibody can be assessed in in vitro or in vivo assays.
  • conservative substitutions are introduced.
  • framework region residues can be mutated, for example, to improve the properties of the antibody.
  • one or more framework residues can be "backmutated" to corresponding germline sequence residues.
  • CDR grafting is another modification of antibody variable region known in the art. Since CDR sequences are responsible for most antibody-antigen interactions, recombinant antibody variants can be constructed that mimic the properties of known antibodies. In this antibody variant, CDR sequences from known antibodies are grafted onto the framework regions of different antibodies with different properties.
  • the invention relates to an anti-LAG-3 antibody, or an antigen-binding fragment thereof, comprising heavy and light chain CDR sequences from one of the antibodies of Table 3, but with different framework region sequences .
  • Framework region sequences for replacement can be obtained from public DNA databases, including germline antibody gene sequences, or from LAG-3 antibody sequences reported in published literature.
  • germline DNA encoding human heavy and light chain variable region genes can be obtained from the GenBank database.
  • the antibody protein sequence can be compared with the protein sequence in the database using a sequence similarity search tool such as Gapped BLAST.
  • the framework sequence used for substitution has structural similarity to the framework sequence of the antibody of the present invention selected for change, for example, having sequence identity of at least 80%, 85%, 90%, or 95%, 96%, 97 %, 98%, 99% or more framework sequences.
  • VH from an exemplary antibody of the invention (one of the antibodies shown in Table 3) and other different anti-LAG-3 antibodies (preferably, the other antibody shown in Table 3) can be "mixed and matched" And VL sequences to generate other antibodies of the invention that bind LAG-3.
  • VH sequences from a specific VH / VL pair with structurally similar VH sequences.
  • VL sequences from a particular VH / VL pair are preferably replaced with structurally similar VL sequences.
  • Such "mixed and matched" antibodies can be tested for binding to LAG-3 using binding assays known in the art (eg, ELISA, and other assays described in the Examples section).
  • the antibody of the invention comprises a heavy chain variable region VH sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 33, 34, 35, 36, 37, and 38, or Consists of the amino acid sequence.
  • an antibody of the invention comprises a variant of said VH sequence.
  • an antibody of the invention comprises a light chain variable region VL sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 39, 40, 41, 42 and 43 or by Amino acid sequence composition.
  • an antibody of the invention comprises a variant of said VL sequence.
  • an antibody of the invention comprises heavy and light chain variable region VH / VL sequence pairs, wherein the VH sequence (i) comprises a group selected from SEQ ID NOs: 33, 34, 35, 36, 37, and 38 The amino acid sequence shown, or consists of the amino acid sequence, or (ii) is a variant of the VH sequence of (i); and the VL sequence comprises (i) selected from SEQ ID NOs: 39, 40, 41, 42 and The amino acid sequence shown in 43, or consists of the amino acid sequence, or (ii) is a variant of the VL sequence of (i).
  • an antibody of the invention comprises a heavy chain variable region and a light chain variable region sequence pair selected from:
  • the variant of the VH sequence is at least 80%, 85% in amino acid sequence compared to the reference VH sequence (preferably over the full length or over the three regions of CDR1, 2 and 3). %, 90%, 92%, 95%, 97%, 98%, 99% or higher identity. In one embodiment, the variant of the VH sequence is at least one and no more than the reference VH sequence (preferably, over the full length or over the three regions of CDR1, 2 and 3) in the amino acid sequence. 30, 10, or 5, 4, 3, 2, 1, 0 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions). Preferably sequence differences do not occur in the CDR regions.
  • the variant of the VL sequence is at least 80% in amino acid sequence compared to the reference VL sequence (preferably over the full length or in the three regions of CDR1, 2 and 3) , 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identity.
  • the variant of the VL sequence is in amino acid sequence, compared to the reference VL sequence, (preferably over the full length or over the three regions of CDR1, 2 and 3), comprising at least one and No more than 30, 10, or 5, 4, 3, 2, 1, 0 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions).
  • sequence differences do not occur in the CDR regions.
  • an antibody of the invention comprises a heavy chain variable region and a light chain variable region VH / VL sequence pair, said VH / VL sequence pair comprising an amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 33/39, 34/39, 35/40, 36/41, 37/42, and 38/43, or consist of the amino acid sequence pair.
  • the invention also provides variants of the antibody, such as variants having at least 95-99% identity on VH, VL, or VH and VL, or comprising no more than 10 amino acid changes.
  • the heavy chain variable region of the antibody variant contains no more than 10, preferably no more than 1 CDR regions on one or more CDR (preferably all 3 CDRs) regions relative to the reference antibody.
  • 5 eg, 3, 2, 1 or 0 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions).
  • the light chain variable region VL of the antibody variant contains no more than 10, preferably not more than 1 CDR regions relative to a reference antibody, on one or more CDRs (preferably all 3 CDRs). More than 5 (e.g., 3, 2, 1 or 0) amino acid changes (preferably amino acid substitutions, preferably conservative substitutions).
  • the antibody of the present invention or an antigen-binding fragment thereof comprises a combination of CDR sequences selected in the order (HCDR1, HCDR2 and HCDR3, LCDR1, LCDR2 and LCDR3, respectively):
  • an antibody of the invention comprises a heavy chain Fc region, such as an Fc region of the IgG1, IgG2, or IgG4 isotype.
  • an antibody of the invention contains an IgG4-Fc region with a serine to proline mutation (S228P) at amino acid residue position 228 (EU numbering).
  • an antibody of the invention comprises an IgG4-PAAFc moiety.
  • the IgG4-PAA Fc portion has a serine to proline mutation (S228P) at position 228, a phenylalanine to alanine mutation at position 234 (EU number), and a leucine at position 235 (EU number) To alanine mutation.
  • the S228P mutation is a mutation in the hinge region of the constant region of tumors, which can reduce or eliminate heterosulfide heterodisulfide bridges.
  • the F234A and L235A mutations can further reduce the effector function of the human IgG4 isotype (which already has low effector function).
  • the antibodies of the invention contain an IgG4-PAA Fc portion with the heavy chain C-terminal lysine (des-Lys) removed.
  • an antibody of the invention comprises a kappa light chain constant region, such as a human kappa light chain constant region.
  • the Fc region comprises the amino acid sequence of SEQ ID NO: 68, or the amino acid sequence of SEQ ID NO: 68 contains at least one, two or three, but not more than 20, 10 Or an amino acid sequence of 5 amino acid changes, or a sequence having at least 95-99% identity with the amino acid sequence of SEQ ID NO: 68.
  • an antibody of the invention comprises a light chain constant region.
  • the light chain constant region is a human kappa light chain constant region.
  • the light chain constant region comprises the amino acid sequence of SEQ ID NO: 69, or the amino acid sequence of SEQ ID NO: 69 contains at least one, two or three, but no more than 20, 10 Amino acid sequence with one or five amino acids changed, or a sequence having at least 95-99% identity with the amino acid sequence of SEQ ID NO: 68.
  • the antibody of the invention comprises a heavy chain
  • the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 44, 45, 46, 47, 48, and 49, or at least one relative thereto, Two or three, but no more than 20, 10, or 5 amino acid sequence changes or at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% Or higher amino acid sequence.
  • the amino acid changes do not occur in the CDR regions, and more preferably, they do not occur in the variable regions.
  • the antibody of the invention comprises a light chain
  • the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 63, 64, 65, 66, and 67, or at least one, two relative to it. Or three, but no more than 20, 10, or 5 amino acid sequence changes, or at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more Highly identical amino acid sequences.
  • the amino acid changes do not occur in the CDR regions, and more preferably, they do not occur in the variable regions.
  • an antibody of the invention comprises a heavy chain sequence and / or a light chain sequence selected from:
  • the variant contains at least one, two or three, but no more than 20, 10 or 5 amino acid altered amino acid sequences compared to the corresponding reference sequence, or has at least 80%, 85%, 90% , 92%, 95%, 97%, 98%, 99% or higher amino acid sequence identity.
  • the amino acid changes do not occur in the CDR regions, and more preferably do not occur in the variable regions.
  • residue modifications are made in the constant region of the antibody to, for example, alter the properties of the antibody, such as effector function.
  • the invention provides fully human antibodies that specifically bind to LAG-3 (eg, human LAG-3) as isolated and characterized in the Examples.
  • LAG-3 eg, human LAG-3
  • the VH and VL sequences of the antibody variable regions of these exemplary antibodies of the invention are listed in Table 3 below.
  • Exemplary CDR sequences of the antibodies are listed in Tables 1 and 2 below.
  • the invention provides variants of any of the antibodies described herein, particularly the exemplary antibodies listed in Table 3.
  • the antibody variant retains at least 60%, 70%, 80%, 90%, or 100% of the biological activity (eg, antigen-binding capacity) of the pre-modified antibody.
  • the alteration does not cause the antibody variant to lose binding to the antigen, but optionally can confer properties such as increased antigen affinity and different effector functions.
  • variable region of the heavy chain or the variable region of the light chain of the antibody, or each CDR region can be changed individually or in combination.
  • the amino acid is changed to an amino acid substitution, preferably a conservative substitution.
  • the amino acid is changed to an amino acid substitution, preferably a conservative substitution.
  • the antibody variant and the reference antibody have at least 80%, 85%, 90%, or 95% or 99% or higher amino acid identity on the region of the target antibody sequence.
  • an antibody of the invention has at least 90%, 91%, 92%, 93% on 3 heavy chain CDR regions compared to a reference antibody (such as one of the antibodies listed in Table 3), 94%, 95%, 96%, 97%, 98%, or 99% or higher identity.
  • an antibody of the invention has at least 90%, 91%, 92%, 93%, 94% of the three light chain CDR regions compared to a reference antibody (eg, one of the antibodies listed in Table 3). , 95%, 96%, 97%, 98%, or 99% or higher identity.
  • an antibody of the invention has at least 90%, 91%, 92%, 93%, 94% of the 6 CDR regions compared to a reference antibody (eg, one of the antibodies listed in Table 3), 95%, 96%, 97%, 98%, or 99% or higher identity.
  • an antibody of the invention has at least 80%, 85%, 90%, 91%, 92% of the heavy chain variable region compared to a reference antibody (such as one of the antibodies listed in Table 3). , 93%, 94%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity. In yet another embodiment, an antibody of the invention has at least 80%, 85%, 90%, 91%, 92% of the light chain variable region compared to a reference antibody (e.g., one of the antibodies listed in Table 3). , 93%, 94%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity. In yet another embodiment, an antibody of the invention has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity.
  • changes can be made to the Fc region of the antibody. Changes in the Fc region can be made alone or in combination with changes to the framework and / or CDR regions described above.
  • the Fc region can be altered, for example, to alter one or more functions of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and / or antigen-dependent cytotoxicity.
  • the antibodies of the invention can also be chemically modified (e.g., linked to PEG) or their glycosylation pattern can be changed.
  • the Fc region may comprise an Fc-region having one or more amino acid substitutions that increase ADCC activity, for example, substitutions at positions 298, 333, and / or 334 of the Fc-region (EU numbering of residues) .
  • changes can also be made to the Fc-region to cause altered (ie, increased or decreased) C1q binding and / or complement-dependent cytotoxicity (CDC) (see, for example, US 6,194, 551, WO99 / 51642 and Idusogie, EE et al., J. Immunol. 164 (2000) 4178-4184).
  • changes can be made to the Fc to increase or decrease its degree of glycosylation and / or change its glycosylation pattern.
  • Addition or deletion of a glycosylation site of an Fc can be conveniently achieved by altering the amino acid sequence in order to create or remove one or more glycosylation sites.
  • one or more amino acid substitutions can be made to eliminate one or more glycosylation sites, thereby eliminating glycosylation at that site.
  • Antibodies with altered types of glycosylation can be made, such as low or no fucosylated antibodies with reduced amounts of fucosyl residues or antibodies with increased bisected GlcNac structures. Such altered glycosylation patterns have been shown to increase the ADCC ability of antibodies.
  • the present invention also contemplates antibody variants having at least one galactose residue in the oligosaccharide linked to the Fc region. These antibody variants may have improved CDC function.
  • the invention also contemplates antibody variants that have some but not all effector functions, which makes them ideal candidates for certain applications in which the in vivo half-life of the antibody is important, but Certain effector functions (such as complement and ADCC) are unnecessary or harmful.
  • the Fc region may contain mutations that eliminate or reduce effector functions, such as a human IgGl Fc region with mutations P329G and / or L234A and L235A, or a human IgG4 Fc region with mutations P329G and / or S228P and L235E.
  • cysteine engineered antibody such as a "thio MAb" wherein one or more residues of the antibody are replaced with cysteine residues.
  • the number of cysteine residues in the hinge region of an antibody can be altered to, for example, facilitate assembly of the light and heavy chains or increase or decrease the stability of the antibody.
  • Residues are, for example, U.S. Patent No. 5,677,425.
  • the antibodies provided herein can be further modified to contain a non-proteinaceous moiety.
  • Suitable antibody-derived moieties include, but are not limited to, water-soluble polymers.
  • Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG) to, for example, increase the half-life of an antibody (eg, serum).
  • PEG polyethylene glycol
  • Methods for PEGylation of proteins are known in the art and can be applied to antibodies of the invention. See for example EP 0154 316 and EP 0401384.
  • the present invention provides a nucleic acid encoding any of the above anti-LAG-3 antibodies or fragments thereof.
  • a vector comprising the nucleic acid is also provided.
  • the vector is an expression vector.
  • a host cell comprising the nucleic acid or the vector is also provided.
  • the host cell is eukaryotic.
  • the host cell is selected from yeast cells, mammalian cells (e.g., CHO cells or 293 cells).
  • the host cell is prokaryotic.
  • the invention provides a nucleic acid encoding any of the above anti-LAG-3 antibodies or fragments thereof.
  • the nucleic acid may comprise a nucleic acid encoding an amino acid sequence of a light chain and / or heavy chain variable region of an antibody, or a nucleic acid comprising an amino acid sequence of a light and / or heavy chain of an antibody.
  • An exemplary nucleic acid sequence encoding an antibody heavy chain variable region comprises at least 80%, 85%, 90%, 91%, 92% of a nucleic acid sequence selected from SEQ ID NO: 57, 58, 59, 60, 61 or 62.
  • nucleic acid sequences or comprise a nucleic acid sequence selected from 57, 58, 59, 60, 61, or 62.
  • Exemplary nucleic acid sequences encoding the variable region of an antibody light chain include at least 80%, 85%, 90%, 91%, 92% of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 50, 51, 52, 53, or 54 , 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical nucleic acid sequences, or include a nucleic acid sequence selected from the group consisting of SEQ ID NO: 50, 51, 52, 53, or 54.
  • the polypeptide encoded by these polynucleotides can show LAG-3 antigen-binding ability.
  • polynucleotides that encode at least one CDR region and generally all three CDR regions from the heavy chain VH or light chain VL sequences of an antibody that binds LAG-3 as described above.
  • the polynucleotide encodes a complete or substantially complete variable region sequence of the heavy and / or light chain of the LAG-3 binding antibody described above.
  • each antibody or polypeptide amino acid sequence can be encoded by a variety of nucleic acid sequences.
  • the nucleic acid of the invention encoding an antibody further comprises a nucleotide sequence encoding a heavy chain Fc region, such as the Fc region sequence shown in SEQ ID NO: 68 or a sequence substantially identical thereto.
  • a nucleic acid of the invention encoding an antibody further comprises a nucleotide sequence encoding a light chain constant region sequence, such as the sequence shown in SEQ ID NO: 69 or a sequence substantially identical thereto.
  • one or more vectors comprising a nucleic acid of the invention are provided.
  • the vector is an expression vector, such as a eukaryotic expression vector.
  • Vectors include, but are not limited to, viruses, plasmids, cosmids, lambda phages, or yeast artificial chromosomes (YAC).
  • YAC yeast artificial chromosomes
  • the expression vector of the invention is a pTT5 expression vector.
  • a host cell comprising the vector.
  • Suitable host cells for cloning or expressing a vector encoding an antibody include prokaryotic or eukaryotic cells described herein.
  • antibodies can be produced in bacteria, especially when glycosylation and Fc effector functions are not required.
  • the expression of antibody fragments and polypeptides in bacteria see, for example, U.S. Pat. , Pages 245-254, which describe the expression of antibody fragments in E. coli). After expression, the antibodies can be isolated from the bacterial cell paste in the soluble fraction and can be further purified.
  • the host cell is eukaryotic.
  • the host cell is selected from yeast cells, mammalian cells, or other cells suitable for use in making antibodies or antigen-binding fragments thereof.
  • eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors encoding antibodies.
  • fungal and yeast strains whose glycosylation pathways have been "humanized” result in the production of antibodies with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22: 1409-1414 (2004), and Li et al., Nat. Biotech. 24: 210-215 (2006).
  • Host cells suitable for expressing glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Vertebrate cells can also be used as hosts.
  • a mammalian cell line adapted to suspension growth can be used.
  • useful mammalian host cell lines are monkey kidney CV1 line (COS-7) transformed with SV40; human embryonic kidney line (293HEK or 293 cells, such as, for example, Graham et al., J. Gen Virol. 36:59 (1977) As described in)).
  • Other useful mammalian host cell lines include Chinese Hamster Ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci.
  • a method of making an anti-LAG-3 antibody comprises culturing a host cell comprising a nucleic acid encoding the antibody under conditions suitable for antibody expression, as provided above, and The antibody is optionally recovered from the host cell (or host cell culture medium).
  • a nucleic acid encoding an antibody (such as the antibody described above) is isolated and inserted into one or more vectors for further cloning and / or expression in a host cell.
  • nucleic acids are easy to isolate and sequence using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding antibody heavy and light chains).
  • anti-LAG-3 antibodies provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activity by a variety of assays known in the art.
  • the antibodies of the invention are tested for their antigen-binding activity.
  • binding to human LAG-3 can be determined by methods known in the art, such as ELISA, Western blot, etc., or exemplary methods disclosed in the examples herein.
  • the assay can be performed using flow cytometry in which the antibody reacts with a cell line expressing human LAG-3, such as HEK293 cells expressing human LAG-3 on the cell surface after transfection. Other cells are also suitable for flow cytometry, including activated CD4 + T cells expressing native LAG-3.
  • the antibody binding including binding kinetics (e.g., K D value), using recombinant LAG-3 protein, in a biological assay of optical interference.
  • a bio-optic interferometry e.g., Fortebio affinity measurement
  • competition assays can be used to identify antibodies that compete for binding to LAG-3 with any of the anti-LAG-3 antibodies disclosed herein.
  • a competitive antibody binds to an epitope (eg, a linear or conformational epitope) that is the same as or overlaps with the epitope bound by any of the anti-LAG-3 antibodies disclosed herein.
  • an epitope eg, a linear or conformational epitope
  • For detailed exemplary methods for locating the epitope bound by an antibody see Morris (1996) "Epitope Mapping Protocols", Methods in Molecular Biology Vol. 66 (Humana Press, Totowa, NJ).
  • the present invention also provides an assay for identifying a biologically active anti-LAG-3 antibody.
  • Biological activities may include, for example, binding to LAG-3 (e.g., binding to human LAG-3), blocking LAG-3 (e.g., binding to human LAG-3) binding to cell surface MHC class II molecules, binding to activated CD4 + and / or CD8 + T cells, inhibit tumor growth.
  • LAG-3 e.g., binding to human LAG-3
  • blocking LAG-3 e.g., binding to human LAG-3
  • binding to activated CD4 + and / or CD8 + T cells inhibit tumor growth.
  • antibodies are tested for their ability to inhibit tumor growth.
  • Antibodies having such biological activity in vivo and / or in vitro are also provided in the present invention.
  • any of the above assays can be performed using an immunoconjugate or multispecific antibody of the invention in place of or in addition to an anti-LAG-3 antibody.
  • the invention provides a multispecific (including bispecific) antibody molecule that specifically binds LAG-3, preferably human LAG-3.
  • an antibody of the invention (or an antigen-binding fragment thereof) forms a first binding specificity for LAG-3.
  • the multispecific antibody is further directed against a second specificity of one of the following, or further comprises a second and third binding specificity directed to two molecules: PD-1, TIM-3, CEACAM (eg, CEACAM-1 or CEACAM-5), PD-L1, or PD-L2.
  • the multispecific antibody is a bispecific antibody that binds LAG-3 and PD-1, binds LAG-3 and PD-L1, or binds LAG-3 and PD-L2.
  • the binding specificity is provided by the "binding site” or "antigen binding site” of the antibody (the region of the antibody molecule that actually binds to the antigen).
  • the antigen binding site consists of a VH / VL pair consisting of an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH).
  • VL antibody light chain variable domain
  • VH antibody heavy chain variable domain
  • a "multispecific" antibody is an antibody having at least two antigen-binding sites, each of said at least two antigen-binding sites may be a different list of the same antigen Or binding to different epitopes of different antigens.
  • the invention provides an immunoconjugate produced by conjugating an antibody of the invention to a heterologous molecule.
  • an antibody (or antigen-binding fragment thereof) of the invention is in a immunoconjugate with a therapeutic or diagnostic agent.
  • an antibody of the invention may be conjugated to a heterologous molecule in the form of a full-length antibody or antibody fragment.
  • conjugation can be performed in the form of Fab fragments, Fab 'fragments, F (ab)' 2 fragments, single-chain scFab antibodies, and single-chain scFv.
  • Linkers can be used to covalently link different entities of the conjugate. Suitable linkers include chemical linkers or peptide linkers.
  • the linker is a "cleavable linker" that facilitates release of the polypeptide upon delivery to the target site.
  • acid labile linkers, peptidase sensitive linkers, photolabile linkers, dimethyl linkers, or disulfide-containing linkers can be used (Chari et al. Cancer 52 (1992) 127-131; US 5,208,020) .
  • Therapeutic agents suitable for use in the conjugate include, but are not limited to, cytotoxins (such as cytostatic agents or cytocidal agents), drugs or radioisotopes.
  • cytotoxic agents eg, chemotherapeutic agents
  • cytotoxic agents include, but are not limited to: radioisotopes; growth inhibitors; enzymes and fragments thereof such as nucleases; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including their Fragments and / or variants; and various known antitumor or anticancer agents.
  • the antibodies of the invention can be conjugated to a diagnostic or detectable agent.
  • a diagnostic or detectable agent can be used as part of a clinical test (such as determining the efficacy of a particular therapy) for monitoring or predicting the onset, formation, progression, and / or severity of a disease or disorder.
  • Such diagnosis and detection can be achieved by coupling antibodies to a detectable agent, including but not limited to a variety of enzymes, such as but not limited to horseradish peroxidase; prosthetic groups, such as but not limited to streptomyces Avidin / biotin and avidin / biotin; fluorescent substances; luminescent substances; radioactive substances; and positron-emitting metals and non-radioactive paramagnetic metal ions used in various positron emission imaging techniques.
  • enzymes such as but not limited to horseradish peroxidase
  • prosthetic groups such as but not limited to streptomyces Avidin / biotin and avidin / biotin
  • fluorescent substances such as but not limited to luminescent substances; radioactive substances; and positron-emitting metals and non-radioactive paramagnetic metal ions used in various positron emission imaging techniques.
  • the present invention also includes a composition (including a pharmaceutical composition or a pharmaceutical preparation) comprising an anti-LAG-3 antibody or an immunoconjugate or a multispecific antibody thereof, and an anti-LAG-3 antibody or an immunoconjugate or a multispecific antibody thereof.
  • a composition comprising an anti-LAG-3 antibody or an immunoconjugate or a multispecific antibody thereof, and an anti-LAG-3 antibody or an immunoconjugate or a multispecific antibody thereof.
  • Polynucleotide composition of sexual antibodies may also optionally contain suitable pharmaceutical excipients, such as pharmaceutical carriers, pharmaceutical excipients, including buffers, as known in the art.
  • the composition further comprises a second therapeutic agent, preferably, an anti-PD-1 antibody.
  • Pharmaceutically acceptable carriers suitable for the present invention can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid carriers, especially for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk , Glycerol, propylene, glycol, water, ethanol, etc.
  • compositions may also contain small amounts of wetting or emulsifying agents, or pH buffering agents.
  • these compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations and the like.
  • Oral formulations may contain standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, saccharin.
  • a pharmaceutical formulation comprising the invention, preferably in the form of a lyophilized formulation or an aqueous solution.
  • Aqueous antibody formulations include those described in US Patent No. 6,171,586 and WO2006 / 044908, the latter formulations including histidine-acetate buffers.
  • the pharmaceutical composition or formulation of the invention may also contain one or more other active ingredients that are required for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other .
  • active ingredients such as chemotherapeutic agents, PD-1 axis binding antagonists (such as anti-PD-1 antibodies or anti-PD-L1 antibodies or anti-PD-L2 antibodies) or anti-angiogenic agents ( (Eg bevacizumab).
  • chemotherapeutic agents such as chemotherapeutic agents, PD-1 axis binding antagonists (such as anti-PD-1 antibodies or anti-PD-L1 antibodies or anti-PD-L2 antibodies) or anti-angiogenic agents ( (Eg bevacizumab).
  • the active ingredients are suitably present in combination in an amount effective for the intended use.
  • sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, eg, films, or microcapsules.
  • the invention also provides a combination product comprising an antibody of the invention or an antigen-binding fragment thereof, and or a fragment or immunoconjugate thereof, and one or more other therapeutic agents (e.g., a chemotherapeutic agent) , Other antibodies, cytotoxic agents, vaccines, anti-infective agents, etc.).
  • other antibodies are, for example, anti-PD-1 antibodies or anti-PD-L1 antibodies or anti-PD-L2 antibodies.
  • the combination product is used to prevent or treat a tumor.
  • the tumor is a cancer, such as a gastrointestinal cancer, such as gastric, rectal, colon, colorectal, and the like; or a skin cancer, such as a malignant melanoma.
  • the combination product is used to prevent or treat infections, such as bacterial infections, viral infections, fungal infections, protozoan infections, and the like.
  • mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., human and non-human primates such as monkeys), rabbits and rodents (e.g., mice and rats mouse).
  • domesticated animals e.g., cows, sheep, cats, dogs, and horses
  • primates e.g., human and non-human primates such as monkeys
  • rabbits and rodents e.g., mice and rats mouse.
  • the subject is a human.
  • treatment refers to a clinical intervention intended to alter the natural process of a disease in an individual being treated.
  • the desired therapeutic effects include, but are not limited to, preventing the appearance or recurrence of the disease, reducing symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or alleviating the state of the disease, and alleviating or improving the prognosis.
  • the invention relates to a method of enhancing an immune response in a subject, said method comprising administering to said subject an effective amount of any of the anti-LAG-3 antibodies or fragments thereof described herein, or An immunoconjugate, a multispecific antibody, or a pharmaceutical composition comprising the antibody or fragment.
  • an anti-LAG-3 antibody or antigen-binding portion thereof of the invention is administered to a tumor-bearing subject to stimulate an anti-tumor immune response.
  • an antibody of the invention or an antigen-binding portion thereof is administered to a subject carrying an infection to stimulate an anti-infective immune response.
  • the invention in another aspect, relates to a method of treating a tumor, such as cancer, in a subject, said method comprising administering to said subject an effective amount of any of the anti-LAG-3 antibodies or fragments thereof described herein, or comprising An immunoconjugate, a multispecific antibody, or a pharmaceutical composition of the antibody or fragment.
  • tumors such as cancers, described herein include, but are not limited to, solid tumors, hematological cancers (eg, leukemia, lymphoma, myeloma) and their metastatic lesions.
  • the cancer is a solid tumor.
  • solid tumors include malignant tumors, such as sarcomas and cancers (e.g., adenocarcinoma) of multiple organ systems, such as invasion of the lung, breast, lymph, gastrointestinal or colorectal, genital and reproductive urinary tract (e.g., kidney cells , Bladder cells, bladder cells), pharynx, CNS (e.g., brain cells, nerve cells or glial cells), skin (e.g., melanoma), head and neck (e.g., head and neck squamous cell carcinoma (HNCC )) And those of the pancreas.
  • malignant tumors such as sarcomas and cancers (e.g., adenocarcinoma) of multiple organ systems, such as invasion of the lung, breast, lymph, gastrointestinal or colorectal, genital and reproductive urinary tract (e.g., kidney cells , Bladder cells, bladder cells), pharynx, CNS (e.g.,
  • melanoma colon cancer, gastric cancer, rectal cancer, renal cell carcinoma, breast cancer (eg, breast cancer that does not express one, two, or all of the estrogen receptor, progesterone receptor, or Her2 / neu, such as , Triple negative breast cancer), liver cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC) (e.g., NSCLC with squamous and / or non-squamous structure) or small cell liver cancer), prostate cancer, head or neck Cancer (eg, HPV + squamous cell carcinoma), small intestine cancer, and esophageal cancer.
  • NSCLC non-small cell lung cancer
  • head or neck Cancer eg, HPV + squamous cell carcinoma
  • small intestine cancer small intestine cancer
  • esophageal cancer e.
  • hematological cancers include, but are not limited to, leukemia (e.g., myeloid leukemia, lymphoid leukemia, or chronic lymphocytic leukemia (CLL)), lymphoma (e.g., Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma or mantle cell lymphoma (MCL)) and myeloma, for example, multiple myeloma.
  • lymphoma e.g., Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma or mantle cell lymphoma (MCL)
  • myeloma for example, multiple myeloma.
  • Cancer can be early, middle or advanced, or metastatic
  • the cancer is a gastrointestinal cancer such as colon cancer, or a skin cancer such as malignant melanoma and the like.
  • the invention in another aspect, relates to a method of treating an infectious disease, such as a chronic infection, in a subject, said method comprising administering to said subject an effective amount of any of the anti-LAG-3 antibodies or fragments thereof described herein Or an immunoconjugate, a multispecific antibody, or a pharmaceutical composition comprising the antibody or fragment.
  • the infection is a viral infection.
  • the infectious disease is caused by a viral infection.
  • pathogenic viruses include (A, B, and C) hepatitis viruses, (A, B, and C) influenza viruses, HIV, herpes viruses (e.g., VZV, HSV-1, HAV-6 , HSV-II, CMV, Epstein Barr virus +), adenovirus, flavivirus, acovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, Rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papilloma, molluscum virus, poliovirus, rabies virus, JC virus and arbovirus.
  • immunoconjugates and multispecific antibodies of the present invention for diseases that are suitable for prevention or treatment with the anti-LAG-3 antibodies or fragments thereof, immunoconjugates and multispecific antibodies of the present invention, further see WO2015 / 138920, WO2016 / 028672, WO2015 / 042246 and the like.
  • the methods described herein further comprise administering to the subject one or more therapies (eg, a treatment modality and / or other therapeutic agent).
  • the treatment modality includes surgical treatment and / or radiation therapy.
  • the methods of the invention include administering at least one other immunostimulatory antibody, such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-1 antibody
  • an anti-PD-1 antibody an anti-PD-L1 antibody
  • an anti-CTLA-1 antibody an anti-CTLA-1 antibody
  • these antibodies can be, for example, fully human, chimeric, or humanized antibodies.
  • the other therapeutic agent is selected from a chemotherapeutic agent, a PD-1 axis binding antagonist (e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody or an anti-PD-L2 antibody) or an anti-angiogenic agent (e.g., shellfish Valizumab).
  • a chemotherapeutic agent e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody or an anti-PD-L2 antibody
  • an anti-angiogenic agent e.g., shellfish Valizumab
  • PD-1 axis binding antagonists include, but are not limited to, PD-1 binding antagonists, PD-L1 binding antagonists and PD-L2 binding antagonists.
  • Alternative names for "PD-1” include CD279 and SLEB2.
  • Alternative names for "PD-L1” include B7-H1, B7-4, CD274, and B7-H.
  • Alternative names for "PD-L2” include B7-DC, Btdc, and CD273.
  • PD-1, PD-L1, and PD-L2 are human PD-1, PD-L1, and PD-L2.
  • a PD-1 binding antagonist is a molecule that inhibits PD-1 from binding to its ligand-binding partner.
  • the PD-1 ligand binding partner is PD-L1 and / or PD-L2.
  • a PD-L1 binding antagonist is a molecule that inhibits PD-L1 from binding to its binding partner.
  • the PD-L1 binding partner is PD-1 and / or B7.1.
  • the PD-L2 binding antagonist is a molecule that inhibits PD-L2 from binding to its binding partner.
  • the PD-L2 binding partner is PD-1.
  • the antagonist may be an antibody, an antigen-binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide.
  • the PD-1 binding antagonist is an anti-PD-1 antibody (eg, a human antibody, a humanized antibody, or a chimeric antibody).
  • the anti-PD-1 antibody is selected from the group consisting of MDX-1106 (nivolumab, OPDIVO), Merck 3475 (MK-3475, pembrolizumab, KEYTRUDA), and CT-011 (Pidilizumab).
  • the anti-PD-1 antibody is MDX-1106.
  • the anti-PD-1 antibody is nivolumab (CAS registration number: 946414-94-4).
  • the anti-PD-1 antibody is an "Antibody D" described herein.
  • an anti-LAG-3 antibody or fragment thereof, alone or in combination with a PD-1 axis binding antagonist, can also be administered in combination with one or more other therapies such as a treatment modality and / or other therapeutic agents.
  • treatment modalities include surgery (e.g., tumor resection); radiation therapy (e.g., exoparticle beam therapy, which involves three-dimensional conformal radiation therapy in which the illuminated area is designed), local irradiation (e.g., pointing at a preselected target) Or organ irradiation) or focused irradiation.
  • an anti-LAG-3 antibody or fragment thereof of the invention can be administered in combination with a chemotherapeutic agent or a chemotherapeutic agent. In some embodiments, an anti-LAG-3 antibody or fragment thereof of the invention can be administered in combination with radiotherapy or a radiotherapy agent. In some embodiments, an anti-LAG-3 antibody or fragment thereof of the invention can be administered in combination with a targeted therapy or a targeted therapeutic agent. In some embodiments, an anti-LAG-3 antibody or fragment thereof of the invention can be administered in combination with an immunotherapy or immunotherapeutic agent, such as a monoclonal antibody.
  • the antibodies of the invention can be administered by any suitable method, including parenteral, intrapulmonary, and intranasal administration, And, if local treatment is needed, it is administered intralesionally.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration.
  • the medication can be administered by any suitable route, such as by injection, such as intravenous or subcutaneous injection.
  • Various dosing schedules are covered herein, including, but not limited to, single administration or multiple administrations at multiple time points, bolus administration, and pulse infusion.
  • an antibody of the invention when used alone or in combination with one or more other therapeutic agents, will depend on the type of disease to be treated, the type of antibody, the severity and progression of the disease , Whether the antibody is administered for preventive or therapeutic purposes, previous treatment, the patient's clinical history and response to the antibody, and the judgment of the attending physician.
  • the antibody is suitably administered to a patient in one treatment or after a series of treatments.
  • the composition, multispecific antibody or immunoconjugate of the present invention can be administered.
  • a composition, a multispecific antibody, or an immunoconjugate of the present invention may be further administered.
  • the present invention provides the use of an anti-LAG-3 antibody, composition, immunoconjugate, multispecific antibody of the present invention in the manufacture of a medicament for use in the aforementioned method (for example, for treatment).
  • the invention relates to a method and kit for detecting LAG-3 in a sample, wherein the method comprises: (a) contacting the sample with an antibody of the invention or an antigen-binding fragment or immunoconjugate thereof; and ( b) detecting the formation of a complex between the antibody or its antigen-binding fragment or immunoconjugate and the LAG-3 protein.
  • the sample is from a cancer patient, such as a skin cancer patient. The detection may be in vitro or in vivo.
  • the term "detection” includes quantitative or qualitative detection. Exemplary detection methods may involve immunohistochemistry, immunocytochemistry, flow cytometry (e.g., FACS), antibody-molecule magnetic beads, ELISA assays Method, PCR-technology (eg, RT-PCR).
  • the biological sample is blood, serum, or other liquid samples of biological origin.
  • the biological sample comprises cells or tissue.
  • the biological sample is from a hyperproliferative or cancerous lesion.
  • the LAG-3 to be detected is human LAG-3.
  • an anti-LAG-3 antibody is used to select a subject suitable for treatment with an anti-LAG-3 antibody, for example where LAG-3 is a biomarker for selecting said subject.
  • a cancer or tumor can be diagnosed using an antibody of the invention, such as to evaluate (e.g., monitor) a subject for the treatment or progression of a disease described herein (e.g., a hyperproliferative or cancerous disease), its diagnosis, and / or Staging.
  • Labels include, but are not limited to, labels or portions that are directly detected (such as fluorescent labels, chromophore labels, electron dense labels, chemiluminescent labels, and radioactive labels), and portions that are detected indirectly, such as enzymes or ligands, for example, Through enzymatic reactions or molecular interactions.
  • Exemplary labels include, but are not limited to, radioisotopes 32P, 14C, 125I, 3H, and 131I, fluorophores such as rare earth chelates or fluorescein and their derivatives, rhodamine and its derivatives, dansyl, umbrella Umbelliferone, luciferase, for example, firefly luciferase and bacterial luciferase (US Patent No.
  • fluorescein 2,3-dihydrophthalazine dione, horseradish peroxidase (HR), alkaline phosphatase, ⁇ -galactosidase, glucoamylase, lyase, sugar oxidase, such as glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, Heterocyclic oxidases such as urase and xanthine oxidase, and enzymes using peroxidase dyes such as HR, lactoperoxidase, or microperoxidase, biotin / avidin , Spin labeling, phage labeling, stable free radicals, and more.
  • HR horseradish peroxidase
  • alkaline phosphatase alkaline phosphatase
  • ⁇ -galactosidase ⁇ -galactosidase
  • glucoamylase lyase
  • the following examples of the present invention relate to six exemplary antibodies (ADI-26818, ADI-26822, ADI-26836, ADI-31798, ADI-31815, and ADI-31836), the CDR regions, light chain variable regions, and heavy chains of these antibodies.
  • the amino acid sequences of the chain variable regions, light and heavy chains, and the corresponding nucleotide sequences are listed in Tables 1-3 and the Sequence Listing of this application.
  • sequence numbers of the light chain constant region, heavy chain constant region, light chain variable region, and heavy chain variable region of the above exemplary antibodies of the present invention are shown in Table 5.
  • Yeast-based antibody presentation libraries were amplified according to existing methods (WO2009036379; WO2010105256; WO2012009568), where the diversity of each library reached 1 ⁇ 10 9 .
  • the first two rounds of screening used Miltenyi's MACS system for magnetically activated cell sorting.
  • FACS washing buffer phosphate buffer, containing 0.1% bovine serum protein
  • the buffer contains 100 nM biotin Human LAG-3 antigen (Acro Biosystems, catalog number LA3-H5255-1 mg).
  • the next round of sorting was performed using a flow cytometer: approximately 1 ⁇ 10 8 of yeast cells obtained after screening by the MACS system were washed three times with FACS buffer, and were labeled with human LAG containing a low concentration of biotin (100-1nM). -3 antigen was cultured at room temperature.
  • the culture medium was discarded, and after washing the cells twice with FACS washing buffer, the cells were mixed with LC-FITC (FITC-labeled anti-human immunoglobulin kappa light chain antibody, Southern Biotech) (diluted 1: 100) and mixed with SA -633 (Streptavidin-633, Molecular Probes) (1: 500 dilution) or SA-PE (Streptavidin-PE, Sigma) (1:50 dilution) reagents were mixed and incubated at 4 ° C for 15 minutes . Eluted twice with pre-chilled FACS wash buffer and resuspended in 0.4 ml buffer, and the cells were transferred to a filter-equipped separation tube. Cells were sorted using FACS ARIA (BD Biosciences).
  • the yeast cells expressing the anti-human LAG-3 antibody obtained by the screening were induced by shaking at 30 ° C for 48 hours to express the anti-human LAG-3 antibody. After induction, the yeast cells were removed by centrifugation at 1300 rpm for 10 min, and the supernatant was harvested. The protein A was used to purify the anti-human LAG-3 antibody in the supernatant, and the pH 2.0 acetic acid solution was used to elute the anti-human LAG-3 antibody. The antibody purity was> 95%.
  • Antibodies ADI-26818, ADI-26822 and ADI-26836 were obtained by screening.
  • This method uses conventional mismatch PCR to introduce mutations into the antibody heavy chain region.
  • the base mismatch probability was increased to about 0.01 bp by using 1uM highly mutated base analogs dPTP and 8-oxo-dGTP.
  • mismatched PCR products were constructed into a vector containing a heavy chain constant region by the method of homologous recombination.
  • the screening pressure including LAG-3 antigen titer, unlabeled antigen competition, and competition using parent antibody, we obtained a secondary library with a library capacity of 1 ⁇ 10 7 .
  • Three successful screenings were performed by FACS method.
  • the CDRH3 gene of the progeny antibody obtained by the VHmut method was constructed into a 1 ⁇ 10 8 diversity CDRH1 / CDRH2 gene library, and 3 rounds of screening were performed. In the first round, the MACS method was used, while in the second and third rounds, the FACS method was used to pressurize the affinity of the antibody-antigen conjugate to select the antibody with the highest affinity.
  • a gene DNA encoding an anti-LAG-3 antibody was obtained from a yeast cell expressing the above-mentioned anti-human LAG-3 antibody, and the gene DNA was cloned into a new expression vector (pTT5) according to a conventional method.
  • the expression vector containing the target antibody gene and the transfection reagent PEI (Polysciences) were transiently transfected into cultured human kidney embryonic cell 293 cells (Invitrogen) according to the protocol provided by the manufacturer. After transfection, the medium was discarded and the cells were diluted to 4 x 10 6 / ml with fresh medium. The cells were cultured at 37 ° C, 5% CO 2 for 7 days, and fresh medium was added every 48 hours. After 7 days, centrifuge at 1300 rpm for 20 min. Take the supernatant and purify the supernatant with Protein A so that the purity of the antibody is> 95%. An IgG4 antibody having an IgG4-PAA Fc portion (SEQ ID No: 68) was obtained.
  • control antibodies used in the examples were expressed and purified in HEK293 cells:
  • 25F7 is a human LAG-3 antibody transiently expressed in HEK293 cells, and its sequence is the same as that of the antibody "25F7" in the US patent US20170137514A1.
  • the full-length heavy and light chains of a 25F7 antibody with an IgG4-PAA Fc portion (SEQ ID No: 68) are shown in SEQ ID No: 55 and SEQ ID NO: 56.
  • the bio-interferometry (ForteBio) assay was used to determine the equilibrium dissociation constant (K D ) of the six exemplary antibodies of the present invention that bind to human LAG-3 (hLAG-3).
  • ForteBio affinity measurement was performed in accordance with existing methods (Estep, P, et al., High Throughput Solution Based Measurement, Antibody-Antigen Affinity and Epitope Binning. MAbs, 2013.5 (2): p.270-8).
  • the sensor was equilibrated in the analysis buffer for 30 minutes below the line, and then detected online for 60 seconds to establish a baseline, and the purified antibody obtained as described above was loaded online to an AHQ sensor (ForteBio) for ForteBio affinity measurement.
  • the sensor with the loaded antibody was exposed to 100 nM of LAG-3 antigen for 5 minutes, and then the sensor was transferred to the analysis buffer for 5 minutes for dissociation rate measurement.
  • Kinetic analysis was performed using a 1: 1 binding model.
  • 293 cells (293-hLAG-3 cells) overexpressing human LAG-3 were generated by transfecting the pCHO1.0 vector (Invitrogen) carrying human LAG-3 cDNA (Sino Biological) cloned to the multicloning site MCS.
  • 293-hLAG-3 cells (0.2 ⁇ 10 6 cells) with different concentrations of experimental antibodies (ADI-26818, ADI-26822, ADI-26836, ADI-31798, ADI-31815, ADI-31836 and control antibody 25F7)
  • Mix antibody dilution method: the highest antibody concentration is 500 nM, three-fold dilution in PBS containing 0.1% bovine serum albumin (BSA), a total of 8 concentrations were tested). Incubate on ice for 30 minutes.
  • the cells were then washed at least twice, a 1: 100 diluted secondary antibody (PE-labeled goat anti-human IgG antibody, Southern Biotech, final concentration 5 ⁇ g / ml) was added, and incubated on ice (protected from light) for 30 minutes. Cells were washed at least twice and analyzed by flow cytometry. Flow cytometry was performed on an Accuri C6 system (BD Biosciences) and a concentration-dependent curve was fitted according to its MFI.
  • a 1: 100 diluted secondary antibody PE-labeled goat anti-human IgG antibody, Southern Biotech, final concentration 5 ⁇ g / ml
  • ADI-26818, ADI-26822, and ADI-26836 bind hLAG-3 overexpressed on HEK293 cells with EC50 values of 1.181nM, 1.500nM, and 1.437nM, respectively. Binding capacity is comparable (EC50 value of control antibody 25F7 is 3.339 nM) (see Figure 1).
  • affinity-optimized anti-hLAG-3 antibodies ADI-31798, ADI-31815, and ADI-31836 bind hLAG-3 overexpressed on HEK293 cells with EC50 values of 0.201 nM and 1.293, respectively. nM and 0.562nM are superior to the binding ability of the control antibody 25F7 to hLAG-3 overexpressed on HEK293 cells (EC50 value 3.339nM). (See Figure 2)
  • ADI-31798, ADI-31815, and ADI-31836 were assessed for the ability of ADI-31798, ADI-31815, and ADI-31836 to block the binding of human LAG-3 to MHCII (HLA) on the cell surface.
  • CHO cells (CHO-DR cells) overexpressing human HLA-DR were generated by transfecting the pCHO1.0 vector (Invitrogen) carrying human HLA-DR (Sino Biological) cloned into MCS.
  • Antigen rhLAG3 protein (huFc) (Sino Biological) was diluted to 40 nM, 50 ⁇ l / well. Add different concentrations of antibodies (ADI-31798, ADI-31815 and ADI-31836 and the control antibody 25F7, starting from the highest concentration of 80nM, three-fold gradient dilution, a total of 8 dilution gradients), 50 ⁇ l / well, incubate on ice in PBS for 30min The final concentration of the antigen is 20nM, and the maximum final concentration of the antibody is 40nM.
  • CHO-DR cells were adjusted to 3 ⁇ 10 5 cells / well, 100 ⁇ l / well.
  • the cells were centrifuged at 300 g for 5 min, the supernatant was discarded, and the cells were resuspended in the antigen-antibody mixture. Incubate on ice for 30 min, add 100 ⁇ l / well PBS, centrifuge at 300 g for 5 min, wash once in PBS, add 100 ⁇ l of goat anti-human IgG-PE (Southern Biotech) / well diluted 1: 100, bath in ice for 20 min, add PBS 100 ⁇ l / well, Centrifuge at 300g for 5 min and wash once in PBS. Resuspend in 100 ⁇ l PBS and measure the fluorescence signal value of the cells with a flow cytometer.
  • the experimental results show that ADI-31798, ADI-31815 and ADI-31836 can effectively block the binding of LAG-3 and its ligand MHCII (HLA-DR), and its blocking ability is equivalent to that of control antibody 25F7.
  • the IC50s of the capabilities of ADI-31798, ADI-31815, and ADI-31836 to block the binding of human LAG-3 and MHCII (HLA-DR) are 4.701 nM, 3.575 nM, and 6.657 nM, respectively.
  • the IC50 of the ability of the control antibody 25F7 to block the binding of human LAG-3 to MHCII (HLA-DR) was 5.141 nM. (See Figure 3)
  • Wells are 150 ⁇ l / well, other wells are 100 ⁇ l / well, antibody is added to the first row of wells, the final concentration is 10nM, mix well, 50 ⁇ l is sucked into the next row of wells, and so on. Make 3 replicates per sample.
  • the experimental results show that ADI-31798, ADI-31815, and ADI-31836 can bind to activated human CD4 + T cells, with EC50 values of 0.00595nM, 0.0128nM, and 0.0127nM, respectively.
  • the binding ability is better than the control antibody 25F7 (the control antibody's EC50 value is 0.0356nM) (see Figure 4).
  • A375 human malignant melanoma skin cancer cells were used to determine the antitumor effect of anti-LAG-3 antibodies on NOG mice.
  • Human PBMCs AllCells
  • A375 tumor-bearing mouse models were established by subcutaneous inoculation. After tumor formation, they were divided into groups and treated with different antibodies.
  • the tumor volume and body weight of mice in each group were monitored during the administration period.
  • the drug frequency is 2 times / week, and the drug is administered for 2 weeks for a total of 5 times.
  • the monitoring frequency is 2 times / week, and the monitoring is continued for 4 weeks.
  • the dosage and method of administration are as follows.
  • TGI% 100% * (h-IgG control group tumor volume-treatment group tumor volume) / (h-IgG control group tumor volume-h- Tumor volume before administration in the IgG control group), where the mean tumor volume before administration in the h-IgG control group was 71 mm 3 .
  • mice NOG mice, female, 7-8 weeks (weeks of age of mice at the time of tumor cell inoculation), weighing 17.6-24.2 g, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. Mice were acclimated for 7 days after arrival, and then began research.
  • Human skin cancer cells A375 (ATCC # CRL-1619) were purchased from ATCC and routinely subcultured in strict accordance with ATCC requirements for subsequent in vivo experiments. Collect the cells by centrifugation, resuspend the cells in sterile PBS and adjust the cell density to 30 ⁇ 10 6 cells / ml. After NOG mice have been intravenously injected with human PBMC, the right back is shaved, and A375 cells are injected subcutaneously at 0.2 ml / head. The tumor volume of each mouse was measured 7 days after tumor cell inoculation, and mice with an average tumor volume in the range of 70-71 mm 3 were selected and randomly grouped according to tumor volume. The antitumor activity of the anti-LAG-3 antibody used alone or in combination with the anti-PD-1 antibody was measured as follows.
  • mice were divided into four groups (6 mice in each group), and each group was injected subcutaneously with the following doses of antibody:
  • Anti-PD-1 antibody (Antibody D, PCT / CN2016 / 094122), 10 mg / kg;
  • Antibody D is an anti-human anti-PD-1 antibody disclosed in PCT / CN2016 / 094122.
  • Human IgG is a human IgG preparation obtained from Equitech-Bio.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

L'invention concerne un anticorps et un fragment d'anticorps qui se lient spécifiquement à LAG-3, ainsi qu'une composition contenant l'anticorps ou le fragment d'anticorps. L'invention concerne également des acides nucléiques codant pour l'anticorps ou un fragment d'anticorps de celui-ci, et une cellule hôte les comprenant, ainsi que des applications thérapeutiques et diagnostiques correspondantes.
PCT/CN2019/091749 2018-06-19 2019-06-18 Anticorps anti-lag-3 complètement humanisé et son application Ceased WO2019242619A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980035403.0A CN112166125B (zh) 2018-06-19 2019-06-18 全人源的抗lag-3抗体及其应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810629554.6 2018-06-19
CN201810629554.6A CN110615840A (zh) 2018-06-19 2018-06-19 全人源的抗lag-3抗体及其应用

Publications (1)

Publication Number Publication Date
WO2019242619A1 true WO2019242619A1 (fr) 2019-12-26

Family

ID=68920063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/091749 Ceased WO2019242619A1 (fr) 2018-06-19 2019-06-18 Anticorps anti-lag-3 complètement humanisé et son application

Country Status (3)

Country Link
CN (2) CN110615840A (fr)
TW (1) TWI721457B (fr)
WO (1) WO2019242619A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113603779A (zh) * 2021-08-18 2021-11-05 深圳市元谷生物科技有限公司 一种结合人淋巴细胞活化基因3(lag-3)的抗体及其用途
WO2023072294A1 (fr) * 2021-11-01 2023-05-04 Elpiscience (Suzhou) Biopharma, Ltd. Nouveaux anticorps anti-lag3

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113348182B (zh) * 2019-12-30 2022-07-12 上海海路生物技术有限公司 Lag-3抗体及其医药用途
WO2022166987A1 (fr) * 2021-02-08 2022-08-11 迈威(上海)生物科技股份有限公司 Anticorps se liant à lag-3 et leur utilisation
MX2024003936A (es) * 2021-09-29 2024-06-28 Akeso Biopharma Inc Anticuerpo anti-lag3, composicion farmaceutica y uso.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103923213A (zh) * 2008-08-11 2014-07-16 梅达雷克斯有限责任公司 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途
CN104411723A (zh) * 2012-07-02 2015-03-11 百时美施贵宝公司 结合淋巴细胞活化基因-3(lag-3)的抗体的优化及该抗体的用途
CN105209494A (zh) * 2013-03-15 2015-12-30 葛兰素史克知识产权开发有限公司 抗lag-3结合蛋白

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US11155617B2 (en) * 2016-06-23 2021-10-26 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
PH12019500668B1 (en) * 2016-10-13 2023-12-06 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103923213A (zh) * 2008-08-11 2014-07-16 梅达雷克斯有限责任公司 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途
CN104411723A (zh) * 2012-07-02 2015-03-11 百时美施贵宝公司 结合淋巴细胞活化基因-3(lag-3)的抗体的优化及该抗体的用途
CN105209494A (zh) * 2013-03-15 2015-12-30 葛兰素史克知识产权开发有限公司 抗lag-3结合蛋白

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113603779A (zh) * 2021-08-18 2021-11-05 深圳市元谷生物科技有限公司 一种结合人淋巴细胞活化基因3(lag-3)的抗体及其用途
WO2023072294A1 (fr) * 2021-11-01 2023-05-04 Elpiscience (Suzhou) Biopharma, Ltd. Nouveaux anticorps anti-lag3

Also Published As

Publication number Publication date
CN112166125B (zh) 2022-09-27
CN112166125A (zh) 2021-01-01
CN110615840A (zh) 2019-12-27
TWI721457B (zh) 2021-03-11
TW202016143A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
JP7488323B2 (ja) 抗ｌａｇ－３抗体および組成物
CA3092456C (fr) Anticorps anti-tigit et utilisation connexe
WO2017071625A1 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
CN112166125B (zh) 全人源的抗lag-3抗体及其应用
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
CN116745324A (zh) 针对cd16a的单域抗体及其用途
CN113330036B (zh) 结合pd-l1和ox40的双特异性抗体
CN112409483A (zh) 抗pd-l1纳米抗体
CN113383017B (zh) 新型双特异性抗体分子以及同时结合pd-l1和lag-3的双特异性抗体
CN111886023B (zh) 针对tim-3的抗体及其用途
WO2022135467A1 (fr) Anticorps anti-b7-h3 et ses utilisations
WO2023001303A1 (fr) Composition pharmaceutique et son utilisation
CN116925222A (zh) 抗pvrig抗体、其药物组合物及用途
WO2024109657A1 (fr) Anticorps anti-ccr8 et son utilisation
JP2024542914A (ja) ヒトｃｘｃｌ１６抗体およびその使用
CA3209827A1 (fr) Anticorps anti-tnfr2 et son utilisation
WO2021175191A1 (fr) Anticorps anti-tim-3 et son utilisation
CN115521379B (zh) Pd-1抗体及其用途
RU2786434C2 (ru) Антитело к tigit и его использование
WO2025113635A1 (fr) Anticorps anti-cd84 et son utilisation
HK40042152B (zh) 抗tigit抗体及其用途
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
KR20240046557A (ko) 항-b7-h4 항체 및 이의 제조 방법과 용도
HK40042152A (en) Anti-tigit antibody and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19823154

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19823154

Country of ref document: EP

Kind code of ref document: A1